Senses Disorder TRIZ Cases

2-substituted indazoles inhibit interleukin-1 receptor-associated kinase 4 to modulate immune signaling pathways.

Prodrug compositions shield peptides from proteolytic degradation using intermediary carriers, enabling effective barrier penetration and reduced side effects.

Novel aminopyrimidine compounds inhibit spleen tyrosine kinase activity to treat inflammatory conditions.

A modified taurine polyphenol conjugate reduces triglyceride levels and exhibits anticoagulant activity.

Fused tricyclic imidazole derivatives inhibit human TNFα activity through potent small molecule binding interactions.

Deuterium substitution at bis-allylic positions stabilizes polyunsaturated fatty acids against oxidation, treating mitochondrial deficiencies.

A 15,15-difluoroprostaglandin F2α derivative inhibits retinal neuronal cell death.

Computer-aided simulation designs novel phage antibody libraries to isolate improved anti-VEGFR-2 monoclonal antibodies with higher affinity and bioactivity.

Fluorinated alpha-2 adrenergic receptor agonists extend intravitreal half-life beyond three hours, countering rapid anterior clearance.

Aldehyde-trapping compounds neutralize inflammatory aldehydes, reducing tissue damage without suppressing the immune system.

Combines a Rho kinase inhibitor with an alpha-1 blocker to promote aqueous outflow.

Carboxyl-modified fructan mediates PHMB interactions to resolve the trade-off between antimicrobial efficacy and ocular irritation.

A combination of rifabutin, clarithromycin, and clofazimine modulates the immune response.

Silanyl-substituted indole 2-carboxamides exhibit specific antagonistic or agonistic activity on TRPV1 receptors.

Antigen binding proteins inhibit TSLP signaling to treat inflammatory and fibrotic disorders without broad anti-inflammatory suppression.

Humanized antibodies bind PDGF-CC epitopes to block angiogenic signaling, reducing tumor growth and edema while stabilizing the blood-brain barrier.

Lateral flow immunoassay measures complement activation via selective antibody binding, eliminating false positives from sample handling delays.

Segmenting steroid molecules into isoquinoline-steroid conjugates reduces intraocular pressure while treating inflammation.

Removing middle kringle domains prevents inclusion body formation and cytotoxicity while maintaining lysine-binding activity.

Optimizing hyaluronic acid concentration to 0.4-0.6 mg/ml preserves antimicrobial activity while maintaining lubricating properties.

Allogeneic T cells reduce viral load and inflammation in solid organ transplant recipients without inducing allograft rejection.

Engineered monoclonal antibodies bind CD122 to inhibit IL-2 and IL-15 signaling, resolving efficacy limits at high affinity receptors.

Substituted 8-[6-amino-3-pyridyl]xanthines selectively block A2B adenosine receptors to treat asthma and diabetes while avoiding insomnia.

Substituted indoline derivatives inhibit the PERK enzyme to treat cancer and neurodegenerative disorders.

Dual histamine H1 and H3 receptor antagonists treat nasal congestion without cardiovascular side effects through segmented receptor targeting.

Novel azaquinazoline carboxamide derivatives inhibit p70S6K while sparing Aurora B kinase to reduce neutropenia toxicity.

Selective inhibitors elevate O-GlcNAc levels to reduce tau phosphorylation.

Local delivery of direct factor Xa and IIa inhibitors targets specific ocular sites, suppressing inflammatory progression while avoiding systemic side effects.

High penetration prodrugs cross biological barriers via covalent transport units to achieve therapeutic concentrations while reducing systemic side effects.

Electromagnetic nanoparticle transport overcomes middle ear inaccessibility, enabling targeted drug delivery.

Truncated linear peptides enable topical application by penetrating the cornea, overcoming the delivery limitations of full-length natriuretic peptides.

Isoform-specific compounds inhibit calpain-2 activation in the retina, resolving neurodegeneration enhancement caused by non-selective inhibitor use.

Novel piperazinylethyl 3-aminopyrrolidine compounds act as potent CCR2 antagonists.

Purine derivatives activate Cannabinoid Receptor 2 to treat pain and inflammation while minimizing unwanted CB1 receptor side effects.

Gly-OiPr delivers cooling sensation in chewing gum while eliminating bitterness and harshness associated with menthol.

Biodegradable polymer conjugates release bioactive moieties via cleavable bonds, resolving uncontrolled dosages from standard admixture methods.

D-proline based synthesis reduces production complexity while maintaining high EP4 receptor affinity and selectivity for therapeutic applications.

Sp35 antagonistic antibodies block inhibitory pathways to promote neuronal survival and axon regeneration in demyelinating disorders.

A pharmaceutical composition combining peroxided oil and cholesterol generates oxygen-centered free radicals to induce apoptosis in cancer cells.

Viral vectors deliver channelrhodopsin-2 genes to inner retinal neurons, converting them into light-sensitive cells.

Cationic lipid carriers deliver anionic chimeric proteins to mammalian cells, resolving genomic insertion risks inherent in DNA transfection methods.